Is downstaging a reliable strategy for expanding criteria for liver transplantation in hepatocellular carcinoma?

Affiliations

¹ Barcelona Clinic Liver Cancer Group (BCLC), HepatoBiliaryPancreatic Surgery and Liver and Pancreas Transplantation Department, ICMDiM, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
² Liver Unit, ICMDiM, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain. Electronic address: aforner@clinic.cat.

Comment

Joana Ferrer-Fàbrega et al. Lancet Oncol. 2020 Jul.

. 2020 Jul;21(7):867-869.

doi: 10.1016/S1470-2045(20)30333-8.

¹ Barcelona Clinic Liver Cancer Group (BCLC), HepatoBiliaryPancreatic Surgery and Liver and Pancreas Transplantation Department, ICMDiM, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
² Liver Unit, ICMDiM, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain. Electronic address: aforner@clinic.cat.

No abstract available

Comment on

Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.
Mazzaferro V, Citterio D, Bhoori S, Bongini M, Miceli R, De Carlis L, Colledan M, Salizzoni M, Romagnoli R, Antonelli B, Vivarelli M, Tisone G, Rossi M, Gruttadauria S, Di Sandro S, De Carlis R, Lucà MG, De Giorgio M, Mirabella S, Belli L, Fagiuoli S, Martini S, Iavarone M, Svegliati Baroni G, Angelico M, Ginanni Corradini S, Volpes R, Mariani L, Regalia E, Flores M, Droz Dit Busset M, Sposito C. Mazzaferro V, et al. Lancet Oncol. 2020 Jul;21(7):947-956. doi: 10.1016/S1470-2045(20)30224-2. Lancet Oncol. 2020. PMID: 32615109 Clinical Trial.